Categories AlphaGraphs, Earnings
Earnings preview: Will CarMax (KMX) stock retain strength after Q3 report?
CarMax Inc. (NYSE: KMX) has been thriving on the steady increase in sales, supported by the effective execution of its growth strategy. The market has responded positively to the upbeat performance in recent quarters and the stock set new records consistently this year.
Bullish Outlook
When the used-car retailer unveils its third-quarter numbers on December 20, before the regular trading session starts, analysts will be looking for earnings of $1.15 per share – up 6% from last year – on revenues of $4.67 billion. Considering the company’s impressive track record of beating estimates, the stock will likely gain further after the earnings announcement and cross the $100-mark for the first time.
It is estimated that volumes moved up in the most recent quarter, helped by the growing demand for used vehicles at affordable prices. There has been an equally encouraging trend in the company’s wholesale segment. While the positive market conditions are set to lift the bottom-line, it will be partially offset by higher selling, general and administrative expenses. It needs to be noted that typically, the company’s margins do not gain as much as sales do.
Omnichannel Push
The management’s initiatives to enhance the omnichannel capabilities have been paying off, making the facility available to more than one-third of the company’s customers. This, combined with the aggressive store-expansion drive and growing online traffic, should translate into revenue growth. Also, the favorable lending environment is expected to attract customers to the showrooms.
Q2 Outcome
In the second quarter, another strong performance by the Used Vehicle segment, which accounts for more than 80% of the company’s revenue, lifted the top-line to $5.2 billion. Consequently, earnings advanced 13% to $1.40 per share, exceeding the expectations.
Also read: Tesla climbs to new high on tax credit talk
CarMax shares traded slightly below the $100-mark ahead of the quarterly report, which is a record high. The stock gained progressively in recent months and is up 48% since the beginning of the year. In the past six months alone it grew 17%.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
Comments
Comments are closed.